MétaCan
Menu
Back to cohort
Record W4415151966 · doi:10.1186/s12943-025-02451-2

Thyroid hormone receptor beta signaling is a targetable driver of prostate cancer growth

2025· article· en· W4415151966 on OpenAlexaff
Aleksandra Fesiuk, Daniel Pölöske, Elvin D. de Araujo, Geordon A. Frere, Gary Tin, Yasir S. Raouf, Olasunkanmi O. Olaoye, Ji Sung Park, Nicolas Blavet, Boris Tichý, Michaela Schlederer, Sandra Högler, Michael Wolf, C. Philippe, Osman Aksoy, Adam Varady, Alejandro Medaglia Mata, Maxim Varenicja, Boglárka Szabó, Theresa R. Weiss, Gabriel Wasinger, Torben Redmer, Heidi A. Neubauer, Martin Susani, Clemens P. Spielvogel, Jing Ning, Maik Dahlhoff, Martin Schepelmann, Richard Kennedy, Richard Moriggl, G. E. Brown, Jenny Persson, Christopher Gerner, Vojtěch Bystrý, Oldamur Hollóczki, David M. Heery, Patrick T. Gunning, Olaf Merkel, Brigitte Hantusch, Lukas Kenner

Bibliographic record

VenueMolecular Cancer · 2025
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsCollege of Family Physicians of CanadaUniversity of Toronto
FundersSiemens HealthineersChristian Doppler ForschungsgesellschaftBundesministerium für Wissenschaft, Forschung und WirtschaftUniversität WienNemzeti Kutatási, Fejlesztési és Innovaciós AlapHungarian Scientific Research FundÖsterreichische ForschungsförderungsgesellschaftMagyar Tudományos AkadémiaVienna Science and Technology FundAustrian Science FundNational Research, Development and Innovation OfficeMinisterstvo Školství, Mládeže a TělovýchovyBundesministerium für Digitalisierung und WirtschaftsstandortMedizinische Universität WienEuropean CommissionÖsterreichische Nationalstiftung für Forschung, Technologie und Entwicklung
KeywordsProstate cancerAndrogen receptorCarcinogenesisThyroid hormone receptorThyroidThyroid cancerCell growthContext (archaeology)Signal transductionReceptor

Abstract

fetched live from OpenAlex

Thyroid hormone (TH) signaling plays a major role in the development, energy homeostasis, and metabolism of most tissues. Recent studies have identified THs as drivers of prostate cancer (PCa) development and progression. We reported that the T3-scavenger protein µ-crystallin (CRYM) regulates the development and progression of PCa and that this involved crosstalk with androgen receptor (AR) signaling. However, the mechanisms remain incompletely understood. Here, we explored the role of thyroid hormone receptor β (TRβ), which is the main effector of TH signaling, in the context of PCa. The use of the TRβ-selective antagonist NH-3 inhibited PCa cell proliferation in vitro and reduced tumor size in PCa xenograft models in vivo. Notably, NH-3 was highly effective in the engrafted 22Rv1 cell line, a model for castration-resistant PCa (CRPC). Mechanistic studies revealed that NH-3 downregulates AR and the AR target genes Nkx3.1 and KLK3 (PSA). NH-3 was a more effective anticancer agent than enzalutamide, and their combined use was synergistic. Evidence from human datasets corroborates our findings, whereby elevated TRβ expression and mutations in the TH signaling pathway are associated with the onset of PCa. Collectively, these results establish TRβ as a mediator of tumorigenesis in PCa and identify NH-3 as a promising therapeutic agent for targeting AR signaling, particularly in CRPC.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.296
Teacher spread0.285 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueMolecular CancerSame topicProstate Cancer Treatment and ResearchFrench-language works237,207